10119- COT-12 ROLE OF GLUCARPIDASE IN DELAYED METHOTREXATE EXCRETION, BASED ON OUR EXPERIENCE

Kazuki Tanimura, Keiko Okada, Rishu Kayatani, Kazuhiro Ueda, Yuki Matsuoka, Kai Yamasaki, Chika Nitani, Hiroyuki Fujisaki, Junichi Hara · 2024

Read 10119- COT-12 ROLE OF GLUCARPIDASE IN DELAYED METHOTREXATE EXCRETION, BASED ON OUR EXPERIENCE by Kazuki Tanimura, Keiko Okada, Rishu Kayatani, Kazuhiro Ueda, Yuki Matsuoka, Kai Yamasaki, Chika Nitani, Hiroyuki Fujisaki, Junichi Hara (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11605565.txt.

Description

Kazuki Tanimura and co-authors review their hospital's experience with glucarpidase, a rescue drug for delayed clearance of high-dose methotrexate, in work published in 2024. Methotrexate is a key drug for brain lymphomas and childhood brain tumours, but slow clearance can quickly damage kidneys and liver. The rescue drug reached Japan in early 2024 with no national guidelines yet.

The review covered fourteen patients treated over nine years, aged from toddler to elderly. Diseases included leukaemia, lymphoma, bone sarcoma, and a brain tumour. At rescue, half had kidney impairment and some had liver enzyme rises. Blood drug levels fell sharply within two days of the first dose, though full clearance took a median of four days. Kidney recovery was slow, taking weeks. The authors share the experience to guide early guideline writing.

Catalog record

CREATORKazuki Tanimura, Keiko Okada, Rishu Kayatani, Kazuhiro Ueda, Yuki Matsuoka, Kai Yamasaki, Chika Nitani, Hiroyuki Fujisaki, Junichi Hara
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11605565

Browse the full library · About the Tower of Babel